Vertex eyes controllable genetic drugs with $1.3bn Obsidian ...

Vertex Pharma has ramped up its involvement in gene-editing medicines for the second time in a week, paying Obsidian Therapeutics $75 million upfront to access its technology platform. 

ASH: CRISPR, Vertex' CTX001 hits the mark in red cell disord...

A gene-editing drug developed by CRISPR Therapeutics and Vertex Pharma has achieved “remarkable” improvements in patients with beta thalassaemia and sickle cell disease in an early-stage tr

CRISPR trials yield encouraging data in blood disorders

FDA gives go-ahead for CRISPR-based sickle cell disease tria...

Development of a stem cell therapy for sickle cell disease from Vertex and development partner CRISPR therapeutics can go ahead, after the FDA lifted a hold on a review.